AstraZeneca plc (ADR)  

(Public, NYSE:AZN)   Watch this stock  
Find more results for AZN
-0.06 (-0.18%)
Nov 30 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 34.03 - 34.24
52 week 29.50 - 37.53
Open 34.16
Vol / Avg. 600.00/3.33M
Mkt cap 86.12B
P/E 50.82
Div/yield 0.45/4.11
EPS 0.67
Shares 1.26B
Beta 0.78
Inst. own 17%
Feb 3, 2016
Full Year 2015 AstraZeneca PLC Earnings Release (Estimated) - 3:00AM EST - Add to calendar
Nov 18, 2015
AstraZeneca PLC at Jefferies Autumn Global Healthcare Conference
Nov 5, 2015
Q3 2015 AstraZeneca PLC Earnings Call - Webcast
Nov 5, 2015
Q3 2015 AstraZeneca PLC Earnings Release
Nov 2, 2015
AstraZeneca PLC at �EBD BIO Europe- Fall
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin 12.95% 4.73%
Operating margin 19.68% 8.19%
EBITD margin - 29.87%
Return on average assets 5.65% 2.16%
Return on average equity 17.34% 5.75%
Employees 57,500 -
CDP Score - 93 A


- Legal Department, 2 Kingdom Street
United Kingdom - Map
+44-20-73045000 (Phone)
+44-20-76048151 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers, develops and commercializes prescription medicines for Cardiovascular and Metabolic diseases; Oncology; Respiratory, Inflammation and Autoimmunity, Infection, Neuroscience and Gastrointestinal. The Company's medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure and angina; Onglyza for Type 2; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Pulmicort for asthma; Symbicort for asthma and COPD (chronic obstructive pulmonary); Nexium for acid-related diseases; Seroquel XR for schizophrenia, bipolar disorder and depressive disorder, and Synagis for RSV (respiratory syncytial virus), a respiratory infection in infants. The Company's pipeline includes 133 projects, of which 118 are in the clinical phase of development. AstraZeneca operates in over 100 countries.

Officers and directors

Pascal Soriot Chief Executive Officer, Executive Director
Age: 56
Bio & Compensation  - Reuters
Marc Dunoyer Chief Financial Officer, Executive Director
Age: 62
Bio & Compensation  - Reuters
Fiona Cicconi Executive Vice-President, Human Resources
Bio & Compensation  - Reuters
Sean Bohen M.D. Ph.D. Chief Medical Officer, Executive Vice President - Global Medicines Development
Bio & Compensation  - Reuters
Ruud Dobber Executive Vice President, Europe
Bio & Compensation  - Reuters
Paul Hudson President, AstraZeneca, US and Executive Vice-President, North America
Bio & Compensation  - Reuters
Bahija Jallal Ph.D. Executive Vice President, MedImmune
Bio & Compensation  - Reuters
Mark Mallon Executive Vice President, International
Bio & Compensation  - Reuters
Luke Miels Executive Vice-President, GPPS
Bio & Compensation  - Reuters
Menelas Pangalos Executive Vice President - Innovative Medicines
Bio & Compensation  - Reuters